David C. Seldin, M.D., Ph.D.

Professor of Medicine and Microbiology
Director, Graduate Program in Molecular Medicine

B.A.  Harvard Collegeseldin_david-2-5x3-5-214x300
M.D.-Ph.D.  Harvard Medical School/M.I.T. Program in Health, Science, & Technology

BUMC Research Profile

My laboratory uses transgenic and knockout mouse models to complement biochemical and cell biological studies of the role of serine-threonine kinases in cellular growth control. Serine and threonine phosphorylation of proteins is much more common than tyrosine phosphorylation, but less well understood. We study a kinase, protein kinase CK2 (casein kinase II), that controls the rate of degradation of critical cellular regulators in the NF-κB (1) and Wnt pathways (2). CK2 itself can behave as an oncogene when expressed in a dysregulated fashion in cells or in the mammary gland (3). The Wnt pathway is also regulated by GSK3β, and these kinases together appear to regulate epithelial/mesenchymal fate decisions of cancer cells, and invasion and metastasis. In addition to characterizing pathological situations in which CK2 dysregulation leads to cancer, we are using gene targeting technology to characterize the essential development roles of the isoforms of CK2 (4). A second area of research in the laboratory is the disease systemic (AL) amyloidosis, in which clonal immunoglobulin light chains form fibrillar deposits in tissues leading to organ failure and death. We are cloning, sequencing and expressing patient amyloidogenic light chains to develop animal models for the pathogenesis and treatment of this clonal plasma cell disease (5).